REC602 – Phase I Stage HPV Bivalent (Type 6/11) Vaccine

We are also developing REC602, a bivalent HPV vaccine candidate targeting HPV 6/11, which is currently performing data evaluation and analysis on the phase I trial in China. We currently expect to complete the phase I trial in 2022 and to submit the BLA application to the NMPA in 2025. REC602 adopts a similar MoA with the recombinant HPV 9-valent vaccine.